Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster modelArticle Published on 2022-01-012022-10-04 Journal: Antiviral Research [Category] SARS, 신약개발, [키워드] airway airway epithelia antiviral drug antiviral molecule antivirals Azithromycin cell lines Clinical course clinical trial concentrations coronavirus COVID-19 COVID-19 pandemic doses drug effective Ex vivo Human Human airway epithelium Hydroxychloroquine identify in vitro in vitro data in vivo inhibitory inhibitory activity lung lung tissue no significant effect quantification SARS-CoV-2 SARS-CoV-2 infections SARS-CoV-2 replication shown Support Syrian hamster. tested the disease Treatment use of hydroxychloroquine viral replication weakness [DOI] 10.1016/j.antiviral.2021.105212 PMC 바로가기 [Article Type] Article
Ex vivo susceptibility to new antimalarial agents differs among human-infecting Plasmodium speciesarticle Published on 2021-12-312024-09-01 Journal: International Journal for Parasitology: Drugs and Drug Resistance [Category] 말라리아, [키워드] drug susceptibility Ex vivo Plasmodium falciparum Plasmodium knowlesi [Article Type] article
Scrutinizing the Feasibility of Nonionic Surfactants to Form Isotropic Bicelles of Curcumin: a Potential Antiviral Candidate Against COVID-19Research Article Published on 2021-12-292022-10-27 Journal: AAPS PharmSciTech [Category] Coronavirus, COVID-19, SARS, [키워드] Against antiviral activity antiviral therapy benefit Bicelles candidate clinical study conditions COVID-19 COVID-19 patients docking ENhance Ex vivo exhibited form hydrophobic drug investigated Liposome mechanism Mixed micelles molecular docking Non-ionic surfactants permeation Phosphatidylcholine Potential SARS-CoV-2 significantly surfactant TEM therapeutic was used [DOI] 10.1208/s12249-021-02197-2 PMC 바로가기 [Article Type] Research Article
Scrutinizing the Feasibility of Nonionic Surfactants to Form Isotropic Bicelles of Curcumin: a Potential Antiviral Candidate Against COVID-19비 이온 성 계면 활성제의 실현 가능성을 면밀히 조사하여 커큐민의 등방성 비 셀을 형성 : Covid-19에 대한 잠재적 인 항 바이러스 후보Research Article Published on 2021-12-292022-09-10 Journal: AAPS PharmSciTech [Category] 치료제, [키워드] Against antiviral activity antiviral therapy benefit Bicelles candidate Clinical studies clinical study conditions COVID-19 COVID-19 patients cremophor EL Curcumin docking drug delivery system ENhance Ex vivo exhibited form hydrophobic drug investigated Liposome mechanism Mixed micelles molecular docking Non-ionic surfactants permeation Phosphatidylcholine Potential SARS-CoV-2 significantly surfactant TEM therapeutic tween was used [DOI] 10.1208/s12249-021-02197-2 PMC 바로가기 [Article Type] Research Article
Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals전염병 및 COVID-19 회복기 개인의 교차 반응성 및 단일 반응성 SARS-CoV-2 CD4+ T 세포Research Article Published on 2021-12-292022-09-10 Journal: PLoS Pathogens [Category] SARS, 치료기술, 치료법, [키워드] Activation allele Amino acid amino acid sequence Amino acid sequences Analysis assays Author CD4+ T cell class common cold common cold coronavirus common cold Coronaviruses common cold virus common cold viruses contributed convalescent convalescent individual convalescent individuals coronavirus COVID-19 cross-react cross-reactive cross-reactivity defined demonstrated Direct dominant epitope DPB1 elicit elicited Endemic epitope Epitopes Ex vivo frequencies Frequency functional HLA-DP HLA-DR identify immunodominant low frequency marker membrane MHC-II naïve individuals nucleocapsid Nucleocapsid proteins overlapping PBMC peptide peptides Potential prevalent Previous studies previous study proportion protective immunity Protein reactive reagent recognizing SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens SARS-CoV-2 epitope SARS-CoV-2 epitopes sequence identity shown spike staining stratified subjects suggested T cell T cell epitope T cell epitopes T cell response T cell responses T cells the Spike to define unlikely viruses was used were used world population [DOI] 10.1371/journal.ppat.1010203 PMC 바로가기 [Article Type] Research Article
Scrutinizing the Feasibility of Nonionic Surfactants to Form Isotropic Bicelles of Curcumin: a Potential Antiviral Candidate Against COVID-19Research Article Published on 2021-12-292022-10-27 Journal: AAPS PharmSciTech [Category] COVID-19, [키워드] Against antiviral activity antiviral therapy benefit Bicelles candidate clinical study conditions COVID-19 COVID-19 patients docking ENhance Ex vivo exhibited form hydrophobic drug investigated Liposome mechanism Mixed micelles molecular docking Non-ionic surfactants permeation Phosphatidylcholine Potential SARS-CoV-2 significantly surfactant TEM therapeutic was used [DOI] 10.1208/s12249-021-02197-2 PMC 바로가기 [Article Type] Research Article
Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 InfectionImmunology Published on 2021-12-232022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, SARS, [키워드] 293T cell ACE2 activated Anti-viral antiviral activity banana Banana Lectin BanLec bind binding CAR CAR-NK cells Cell cellular chimeric antigen receptor circulating COVID-19 Culture divorce effector cells Ex vivo expressed expressing Extracellular glycan glycobiology Immunotherapy infected cells Infection Inflammatory cytokine lectin lentiviral NK cell Patient Point mutation promote Protein pseudotyped receptor Receptor binding domain reduced S-protein SARS-CoV-2 SARS-CoV-2 envelope SARS-COV-2 infection SARS-CoV-2 virus secrete spike the SARS-CoV-2 therapeutic therapy viral clearance virus wild-type SARS-CoV-2 [DOI] 10.3389/fimmu.2021.763460 PMC 바로가기 [Article Type] Immunology
PD-1 blockade counteracts post–COVID-19 immune abnormalities and stimulates the anti–SARS-CoV-2 immune responsePD-1 봉쇄는 코비드 -19 면역 이상을 반대하고 항 -SARS-COV-2 면역 반응을 자극합니다.Research Article Published on 2021-12-222022-08-31 Journal: JCI Insight [Category] SARS, 바이오마커, [키워드] abnormality Alter Altered among others Anergy blockade CD8 characterized coronavirus coronavirus disease coronavirus disease-2019 counteract COVID-19 COVID-19–related symptom COVID-19–related symptoms Ex vivo healthy controls hospital discharge IL-1 IL-1 β IL-1ra IL-8 immune Immune checkpoint blockade immune response immunologically immunology Immunotherapy Infection lentivirus Methylation Neutralization assay neutralize nonspecific normalized Patient patients PD-1 PD-L1 PD1 peptides plasma Plasma level Plasma levels promoter proportion pseudotyped reduced restored SARS-CoV-2 antigens SARS-CoV-2 peptides SARS-CoV-2 spike stimulate T cell T cell response T cells [DOI] 10.1172/jci.insight.146701 PMC 바로가기 [Article Type] Research Article
Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study지속적인 양압 인공호흡기 지원이 필요한 중증 코로나바이러스 질환 2019(COVID-19) 환자의 에쿨리주맙: 후향적 코호트 연구Observational Study Published on 2021-12-202022-09-12 Journal: PLoS ONE [Category] Coronavirus, MERS, 임상, 진단, [키워드] 95% CI age baseline baseline characteristics blockade change changes in Characteristics cohort study Complement activation Complication complications confirmation contribute Control controls coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 patient CPAP creatinine discharge discharged disease dose dysfunction eculizumab Endpoint Ex vivo finding IMPROVE IQR limitation lung dysfunction median Mortality outcome over Patient patients patients died positive airway pressure pressure Primary outcome Randomised controlled trials receiving respiratory rate Result SC5b-9 secondary Secondary outcomes serum creatinine severe coronavirus disease severe COVID-19 Sex significantly small sample size Standard therapy Support thrombi ventilator [DOI] 10.1371/journal.pone.0261113 PMC 바로가기 [Article Type] Observational Study
A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virusArticle Published on 2021-12-092022-10-04 Journal: Nature Medicine [Category] 비임상, 임상, 치료제, [키워드] Administered Adverse antibody approved arthralgia Arthritis cause characterized Chikungunya virus clinical trial Concentration conducted detectable disease dose dose-dependent Effect evaluate evaluated Ex vivo expression Fever functional healthy Human IgG IgG level immunocompromised individual Immunoglobulin in vivo Infant Infection Infectious diseases interim analysis intravenous knowledge Messenger RNA Mild moderate monoclonal monoclonal antibody mRNA mRNA-based Neutralizing Neutralizing activity neutralizing antibody offer participant patients phase 1 trial Placebo placebo-controlled plasma concentration predicted Preventive medicine Primary outcome Randomized Rash serum severity single dose therapeutic therapeutic use therapy Tolerability Treatment Trial viral infection [DOI] 10.1038/s41591-021-01573-6 PMC 바로가기 [Article Type] Article